HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers (NCT07126561) | University of Chicago | 2026-11-01 |
Track HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2 automatically
Every clearance here is in the API, with alerts when new ones post.